Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 706 and Octreotide in Low-Grade Neuroendocrine Tumors
NCT00427349Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Nov 2008
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of motesanib in Neuroendocrine Neoplasm (NEN), sponsored by Eastern Cooperative Oncology Group. Started Nov 2008; status: completed.
02
Drugs
motesanib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00427349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427349.